methyl 3-hydroxy-4-methyl-1-naphthoate | 465536-26-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl 3-hydroxy-4-methyl-1-naphthoate
• 英文别名: Methyl 3-hydroxy-4-methylnaphthalene-1-carboxylate
• CAS: 465536-26-9
• 化学式: C₁₃H₁₂O₃
• 分子量: 216.236
• InChiKey: RDZAWCMCZMJEQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3-hydroxy-4-methyl-1-naphthoate 在 四(三苯基膦)钯 lithium hydroxide 、 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 N-[2-(S)-(3,4-dichlorophenyl)-4-[4-[(S)-2-methylsulfinylphenyl]-1-piperidinyl]butyl]-N-methyl-3-cyano-6-methyl-1-naphthamide
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i
• 作为产物：
  描述：

  methyl 4-iodo-3-methoxy-1-naphthoate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride potassium phosphate 、 吡啶盐酸盐 、 碳酸氢钠 作用下， 以 四氢呋喃 、 丙酮 为溶剂， 反应 38.0h， 生成 methyl 3-hydroxy-4-methyl-1-naphthoate
  参考文献：
  名称：

  Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity

  摘要：

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.

  DOI：

  10.1021/jm020094i

文献信息

• Design, Synthesis, and SAR of Tachykinin Antagonists:  Modulation of Balance in NK₁/NK₂ Receptor Antagonist Activity
  作者：Jeffrey S. Albert、David Aharony、Donald Andisik、Herbert Barthlow、Peter R. Bernstein、Russell A. Bialecki、Robert Dedinas、Bruce T. Dembofsky、Daniel Hill、Karin Kirkland、Gerard M. Koether、Benedict J. Kosmider、Cyrus Ohnmacht、William Palmer、William Potts、William Rumsey、Lihong Shen、Ashok Shenvi、Scott Sherwood、Paul J. Warwick、Keith Russell

  DOI：10.1021/jm020094i

  日期：2002.8.1

  Through optimization of compounds based on the dual NK1/NK2 antagonist ZD6021, it was found that alteration of two key regions could modulate the balance of NK1 and NK2 potency. Substitution of the 2-naphthalene position in analogues of ZD6021 resulted in increased NK1 potency and thus afforded NK1 preferential antagonists. Alterations of the piperidine region could then increase NK2 potency to restore dual NK1/NK2 selectivity. Through these efforts, three novel receptor antagonists from a single chemically related series were identified; two are dual NK1/NK2 antagonists, and the third is an NK1 preferential antagonist. In this paper, the factors affecting the balance of NK1 and NK2 selectivity in this series are discussed and the in vitro and in vivo properties of the novel antagonists are described.